Inhalative application of soluble guanylyl cyclase stimulator BAY 41–8543 for treatement of pulmonary arterial hypertension
V Amirjanians, B Egemnazarov, A Sydykov, B Kojonazarov, H Luitel, N Weissmann, F Grimminger, W Seeger, R Schermuly, HA Ghofrani · Pneumologie · 2010 · Heft 03
Bibliografische Angaben
Zusammenfassung
Background. Pulmonary arterial hypertension (PAH) is a devastating disease with a pure outcome. Recently, a new class of medicines has been proposed for treatment of the disease – soluble guanylyl cyclase stimulators. The possible drawback of the drugs is the potential of systemic arterial hypotension. Therefore, we sought to achieve the pulmonary selectivity of the BAY 41–8543 effects by inhalative application. Methods. The model of monocrotaline (60kg/kg s.c.) induced PAH in rats was applied. Four weeks after monocrotaline injection, treatment for two weeks with vehicle, BAY 41–8543 10mg/kg peroral gavage (PO)…
